Cysteine derivative · Fact sheet
N-acetylcysteine
Also known as NAC · Acetylcysteine
N-acetylcysteine has established medical uses, including the approved Acetadote product for acetaminophen poisoning. Claims about compulsive behavior, mental health, and general antioxidant wellness have separate, more limited evidence.
What is N-acetylcysteine?
NAC supplies cysteine involved in glutathione synthesis and has been studied in glutamate signaling. Approved medicinal formulations and consumer supplements are not interchangeable.
Benefits people look for
Liver protection, fewer compulsive urges, respiratory effects, and antioxidant support attract interest. An antidote indication cannot be generalized to routine detox or prevention.
What the evidence supports
- Acetadote is an approved treatment to prevent or lessen liver injury after potentially toxic acetaminophen exposure.
- Adult hair-pulling findings did not reproduce in the pediatric trial and do not establish broad mental-health benefits.
All research areas
- Acetaminophen poisoning
- Trichotillomania
- Glutathione and glutamate pathways
Anecdotal reports & lived experiences
Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens.
No attributable personal reports are summarized here yet. The benefits above describe research interests; the side effects below come from the cited medical sources.
We do not fill this gap with unsourced testimonials or estimated success rates.
Side effects & risks
- The Acetadote label warns about serious hypersensitivity reactions, including rash, low blood pressure, breathing difficulty, and bronchospasm.
- Fluid overload is a formulation- and treatment-context risk described in the label. These risks should not be converted into side-effect rates for unrelated oral products.
This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.
Clinical research: how strong is it?
Moderate human evidenceApproval evidence applies to a defined poisoning indication. A 50-adult hair-pulling trial was positive, while a 39-participant pediatric trial was not; the psychiatric evidence is preliminary and population-specific.
Selected research to read
50-adult, 12-week placebo-controlled trial with improved hair-pulling symptoms.
39 children and adolescents; no significant benefit over placebo.
FDA approval & research status
Acetadote is FDA approved to prevent or lessen liver injury after potentially hepatotoxic acetaminophen ingestion in adults and pediatric patients weighing at least 5 kg. This does not approve NAC supplements for mental-health or wellness claims.
Approved uses covered here
- Acetadote: prevention or reduction of liver injury after potentially toxic acetaminophen ingestion in the labeled population
Approved antidote; other claims separate
Acetadote is FDA approved to prevent or lessen liver injury after potentially hepatotoxic acetaminophen ingestion in adults and pediatric patients weighing at least 5 kg. This does not approve NAC supplements for mental-health or wellness claims.
This summarizes the cited product or research record. Trial phases do not establish successful completion of earlier stages, and a stopped program is not ongoing development. Approval applies only to the labeled product, use and population.
What we still don’t know
- Which psychiatric populations benefit reproducibly
- Long-term wellness outcomes
- Comparability of supplement and approved-product exposures
The takeaway
NAC has a clear medical role, but evidence for each additional claim must stand on its own.
Sources & further reading
Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.
- 1fdaFDA: Acetadote prescribing information
Approved poisoning indication and product-specific warnings.
- 2pubmedNAC in adults with trichotillomania
50-adult, 12-week placebo-controlled trial with improved hair-pulling symptoms.
- 3pubmedNAC in pediatric trichotillomania
39 children and adolescents; no significant benefit over placebo.